BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wilkowski R, Wolf M, Heinemann V. Primary advanced unresectable pancreatic cancer. Recent Results Cancer Res. 2008;177:79-93. [PMID: 18084950 DOI: 10.1007/978-3-540-71279-4_10] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Kim L, Nguyen N, Singhal N, Phan VA, Iankov I, Le H. Application of stereotactic body radiotherapy in advanced pancreatic cancers in Australia. J Med Radiat Sci 2019;66:54-61. [PMID: 30411540 DOI: 10.1002/jmrs.313] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
2 Oliveira MC, Correia JDG. Clinical application of radioiodinated antibodies: where are we? Clin Transl Imaging. [DOI: 10.1007/s40336-021-00477-2] [Reference Citation Analysis]
3 Guan YS, Zou Q, He Q. Invading and long-lasting enormous pancreatic head tumor. Pancreas 2010;39:112-4. [PMID: 20019570 DOI: 10.1097/MPA.0b013e3181b65e07] [Reference Citation Analysis]
4 Duan L, Ying G, Danzer B, Perez RE, Shariat-Madar Z, Levenson VV, Maki CG. The prolyl peptidases PRCP/PREP regulate IRS-1 stability critical for rapamycin-induced feedback activation of PI3K and AKT. J Biol Chem 2014;289:21694-705. [PMID: 24936056 DOI: 10.1074/jbc.M114.550038] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
5 Syed AR, Carleton NM, Horne Z, Dhawan A, Bedi G, Kochhar G, Morrissey S, Williams H, Atkinson D, Schiffman S, Monga D, Lupetin A, Kirichenko A, Mitre M, Dhawan M, Kulkarni A, Thakkar S. Survival Trends for Resectable Pancreatic Cancer Using a Multidisciplinary Conference: the Impact of Post-operative Chemotherapy. J Gastrointest Cancer 2020;51:836-43. [PMID: 31605289 DOI: 10.1007/s12029-019-00303-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Oliverius M, Kala Z, Varga M, Gürlich R, Lanska V, Kubesova H. Radical surgery for pancreatic malignancy in the elderly. Pancreatology 2010;10:499-502. [PMID: 20720452 DOI: 10.1159/000288705] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
7 Okamoto K, Koyama I, Miyazawa M, Toshimitsu Y, Aikawa M, Okada K, Imabayashi E, Matsuda H. Preoperative 18[F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts early recurrence after pancreatic cancer resection. Int J Clin Oncol. 2011;16:39-44. [PMID: 20862596 DOI: 10.1007/s10147-010-0124-z] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
8 Shangguan A, Shang N, Figini M, Pan L, Yang J, Ma Q, Hu S, Eresen A, Sun C, Wang B, Velichko Y, Yaghmai V, Zhang Z. Prophylactic dendritic cell vaccination controls pancreatic cancer growth in a mouse model. Cytotherapy 2020;22:6-15. [DOI: 10.1016/j.jcyt.2019.12.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Pavlidis TE, Pavlidis ET, Sakantamis AK. Current opinion on lymphadenectomy in pancreatic cancer surgery. Hepatobiliary Pancreat Dis Int 2011;10:21-5. [PMID: 21269930 DOI: 10.1016/s1499-3872(11)60002-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
10 Xu C, Li H, Su C, Li Z. Viral therapy for pancreatic cancer: tackle the bad guys with poison. Cancer Lett 2013;333:1-8. [PMID: 23354590 DOI: 10.1016/j.canlet.2013.01.035] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
11 Zeng M, Feng Q, Lu M, Zhou J, Yang Z, Tang J. Predictive role of skin rash in advanced pancreatic cancer patients treated with gemcitabine plus erlotinib: a systematic review and meta-analysis. Onco Targets Ther 2018;11:6633-46. [PMID: 30349297 DOI: 10.2147/OTT.S168418] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 O'Neill C, Hayat T, Hamm J, Healey M, Zheng Q, Li Y, Martin RCG 2nd. A phase 1b trial of concurrent immunotherapy and irreversible electroporation in the treatment of locally advanced pancreatic adenocarcinoma. Surgery 2020;168:610-6. [PMID: 32631655 DOI: 10.1016/j.surg.2020.04.057] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
13 Dhayat SA, Abdeen B, Köhler G, Senninger N, Haier J, Mardin WA. MicroRNA-100 and microRNA-21 as markers of survival and chemotherapy response in pancreatic ductal adenocarcinoma UICC stage II. Clin Epigenetics 2015;7:132. [PMID: 26705427 DOI: 10.1186/s13148-015-0166-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
14 Doria C, De Deyne P, Dolan S, Chung J, Yatcilla K, Zarifian L, Remstein R, Schwartz E. Municipality and Adjusted Gross Income Influence Outcome of Patients Diagnosed with Pancreatic Cancer in a Newly Developed Cancer Center in Mercer County New Jersey, USA, a Single Center Study. Cancers (Basel) 2021;13:1498. [PMID: 33805136 DOI: 10.3390/cancers13071498] [Reference Citation Analysis]
15 Belfiore G, Belfiore MP, Reginelli A, Capasso R, Romano F, Ianniello GP, Cappabianca S, Brunese L. Concurrent chemotherapy alone versus irreversible electroporation followed by chemotherapy on survival in patients with locally advanced pancreatic cancer. Med Oncol 2017;34. [DOI: 10.1007/s12032-017-0887-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
16 Hwang JP, Lim I, Chang KJ, Kim BI, Choi CW, Lim SM. Prognostic value of SUVmax measured by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography with Computed Tomography in Patients with Pancreatic Cancer. Nucl Med Mol Imaging. 2012;46:207-214. [PMID: 24900062 DOI: 10.1007/s13139-012-0151-y] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
17 Anzidei M, Marincola BC, Bezzi M, Brachetti G, Nudo F, Cortesi E, Berloco P, Catalano C, Napoli A. Magnetic Resonance–Guided High-Intensity Focused Ultrasound Treatment of Locally Advanced Pancreatic Adenocarcinoma: Preliminary Experience for Pain Palliation and Local Tumor Control. Investigative Radiology 2014;49:759-65. [DOI: 10.1097/rli.0000000000000080] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
18 Forssell H, Wester M, Akesson K, Johansson S. A proposed model for prediction of survival based on a follow-up study in unresectable pancreatic cancer. BMJ Open 2013;3:e004064. [PMID: 24345902 DOI: 10.1136/bmjopen-2013-004064] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
19 Azari FS, Vollmer CM Jr, Roses RE, Keele L, DeMatteo RP, Drebin JA, Lee MK 4th. A contemporary analysis of palliative procedures in aborted pancreatoduodenectomy: Morbidity, mortality, and impact on future therapy. Surgery 2020;168:1026-31. [PMID: 32888713 DOI: 10.1016/j.surg.2020.06.041] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Masu T, Atsukawa M, Nakatsuka K, Shimizu M, Miura D, Arai T, Harimoto H, Kondo C, Kaneko K, Futagami S, Kawamoto C, Takahashi H, Iwakiri K. Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression. PLoS One 2018;13:e0200664. [PMID: 30596643 DOI: 10.1371/journal.pone.0200664] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
21 Rahman SH, Urquhart R, Molinari M. Neoadjuvant therapy for resectable pancreatic cancer. World J Gastrointest Oncol 2017; 9(12): 457-465 [PMID: 29290916 DOI: 10.4251/wjgo.v9.i12.457] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
22 Yu IS, Cheung WY. A Contemporary Review of the Treatment Landscape and the Role of Predictive and Prognostic Biomarkers in Pancreatic Adenocarcinoma. Can J Gastroenterol Hepatol 2018;2018:1863535. [PMID: 29623263 DOI: 10.1155/2018/1863535] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
23 Nagai S, Fujii T, Kodera Y, Kanda M, Sahin TT, Kanzaki A, Yamada S, Sugimoto H, Nomoto S, Takeda S, Morita S, Nakao A. Prognostic implications of intraoperative radiotherapy for unresectable pancreatic cancer. Pancreatology 2011;11:68-75. [PMID: 21525774 DOI: 10.1159/000324682] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
24 Emori T, Ashida R, Tamura T, Kawaji Y, Hatamaru K, Itonaga M, Yamashita Y, Shimokawa T, Higashino N, Ikoma A, Sonomura T, Kawai M, Kitano M. Contrast-enhanced harmonic endoscopic ultrasonography for predicting the efficacy of first-line gemcitabine and nab-paclitaxel chemotherapy in pancreatic cancer. Pancreatology 2022. [DOI: 10.1016/j.pan.2022.04.005] [Reference Citation Analysis]